UK Begins Clinical Trials for Personalized Cancer Vaccines

NHS aims to revolutionize cancer treatment with custom mRNA-based vaccines designed to prevent recurrence.

First patient receives personalized cancer vaccine as part of NHS trial.
Vaccines use mRNA technology to target specific mutations in cancer cells.
Trials initially focus on colorectal, pancreatic, skin, lung, bladder, and kidney cancers.
Thousands of patients expected to participate in trials across 30 NHS sites.
Preliminary data to be presented at upcoming American Society of Clinical Oncology conference.